4 European Projects Found
Searched on 125080 European Projects
FINISHED
Universal Flu Vaccine (UNIVACFLU)
Start date: Nov 1, 2013, End date: Oct 31, 2017,
Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.The aim is to ...
Read Project
8
Partners Participants
FINISHED
Universal Influenza Vaccines Secured (UNISEC)
Start date: Oct 1, 2013, End date: Sep 30, 2017,
UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of sc ...
Read Project
15
Partners Participants
FINISHED
Nasal Pandemic Influenza Vaccine (NASPANVAC)
Start date: May 1, 2008, End date: Apr 30, 2012,
"The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan ...
Read Project
8
Partners Participants
FINISHED
Dose sparing and increased immunogenicity of a pandemic influenza vaccine by CoVaccine HT (FLUVAC)
Start date: Oct 1, 2007, End date: Sep 30, 2011,
The risk of a new influenza pandemic is emphasized by a WHO report documenting several hundreds of recent cases of human infection with a new virus strain and approximately 50% mortality. Control or prevention of a pandemic by emergency vaccination depends on availability of products with high efficacy and broad protection. The combination of an effective adjuvant and cell culture technology for a ...
Read Project
